{"url_path":"/sec/xers/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000034-index.html","accession_number":"0001867096-26-000034","cik":"0001867096","ticker":"XERS","issuer_name":"Xeris Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867096/0001867096-26-000034-index.html","primary_entity_key":"0001867096","primary_entity_name":"Xeris Biopharma Holdings, Inc."},"word_count":396,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 4, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 172,625,762 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting, of which 128,268,073 shares were present in person virtually or represented by proxy at the Annual Meeting, constituting a quorum on all matters voted upon. Shares present virtually during the Annual Meeting were considered shares represented in person at the Annual Meeting. The final voting results of the Annual Meeting are as follows:\n\nProposal One: Election of Directors\n\nAs described in the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 23, 2026 (the “Proxy Statement”), the Company’s Board of Directors nominated two individuals to serve as Class II directors until the Company’s 2029 Annual Meeting of Stockholders, or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. Each nominee was elected by a plurality vote in accordance with the Company’s Amended and Restated Bylaws, as follows:\n\nClass II Director NomineeForWithholdBroker Non-Votes\n\nDawn Halkuff62,581,57724,906,16640,780,330\n\nJohn Johnson52,665,07734,822,66640,780,330\n\nProposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\nForAgainstAbstainBroker Non-Votes\n\n125,789,8181,032,5301,445,725—\n\nProposal Three: Advisory Vote to Approve Named Executive Officer Compensation\n\nThe Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation for the Company’s named executive officers pursuant to the Say-on-Pay Vote:\n\nForAgainstAbstainBroker Non-Votes\n\n82,230,2044,658,035599,50440,780,330\n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 5, 2026Xeris Biopharma Holdings, Inc.\n\nBy:/s/ Steven M. Pieper\n\nName: Steven M. Pieper\n\nTitle: Chief Financial Officer"}